Abstract
The absorbed doses in the liver and adjacent viscera in Yttrium‐90 radioembolization therapy for metastatic liver lesions are not well‐documented. We sought for a clinically practical way to determine the dosimetry of this advent treatment. Six different female XCAT BMIs and seven different male XCAT BMIs were generated. Using Monte Carlo GATE code simulation, the total of 100MBq 90Y was deposited uniformly in the source organ, liver. Self‐irradiation and absorbed doses in lung, kidney and bone marrow were calculated. The mean energy of Yittrium‐90 (i.e., 0.937 MeV) was used. The S‐values and equivalent doses in target organs were estimated. The dose absorbed in the liver was between 84 and 53 Gy and below the target of 80 to 150 Gy. The absorbed dose in the bone marrow, lungs, and kidneys are very low and below 0.1 , 0.4, and 0.5 Gy respectively. Our study indicates that larger activities than the conventional dose of 3 GBq may be both required and safe. Further confirmations in clinical settings are needed.
Highlights
The treatment of inoperable liver metastases with microspheres and particles labeled with isotopes is a promising hope for a condition once was regarded untreatable.[1,2,3,4,5] The procedure is evolving and the radiations to lungs, preserved liver parenchyma, and the bone marrow in repeated treatments are the limiting concern
The equivalent dose within the liver is generally about 1 mSiv/h while the dose to the bone marrow is below 0.003 mSiv/h and the equivalent dose to the kidney and lung is below 0.03 mSiv in females (Fig. 2) and 0.027 in males (Fig. 4)
We documented the dose to the liver and some critical organs after 90Y-Microsphere therapy for liver metastases
Summary
The treatment of inoperable liver metastases with microspheres and particles labeled with isotopes is a promising hope for a condition once was regarded untreatable.[1,2,3,4,5] The procedure is evolving and the radiations to lungs, preserved liver parenchyma, and the bone marrow in repeated treatments are the limiting concern. Patient’s dosimetry is possible with simulation methods before the initiation of the treatment or can be calculated after the treatment for followup purposes. 90Y became available to us and labeling of the microspheres and clinical trials are under development.[8,9,10] There are different methods for internal dosimetry and imaging of the 90Y.11. 90Y became available to us and labeling of the microspheres and clinical trials are under development.[8,9,10] There are different methods for internal dosimetry and imaging of the 90Y.11 In this study, we provide a radiation dose estimate to major target organs after treatment of liver metastases with the 90Y
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
